Membrane expression of the death ligand trail receptors DR4 and DR5 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer. (July 2013)

• Record Type: Journal Article
• Authors: Gottwald, L.; Szwalski, J.; Piekarski, J.; Pasz-Walczak, G.; Kubiak, R.; Spych, M.; Suzin, J.; Tyliński, W.; Sęk, P.; Jeziorski, A.
• Is Part Of: Journal of obstetrics and gynaecology. Volume 33:Number 5(2013)
• Page Start: 512
• Page End: 518
• Publication Date: 2013-07
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; 618.05
• DOI: 10.3109/01443615.2013.790886
• Languages: English
• ISSNs: 0144-3615

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>To assess membrane expression of DR4 and DR5 in the normal endometrium (NE), endometrial atypical hyperplasia (EAH) and endometrioid endometrial cancer (EEC), the study examined 101 patients: 20 NE, 14 EAH and 67 EEC. The expression of DR4 and DR5 was examined and presented as the total score (TS). DR4 expression was seen in 18 NE, 11 EAH and 10 EEC. DR5 expression was seen in 20 NE, 13 EAH and 21 EEC. A strong correlation between type of endometrial tissue and TS of both receptors was identified. In EEC TS of DR4 and DR5 was not related to grading, staging or survival. Malignant transformation in the endometrium is related to reduction of membrane DR4 and DR5 expression. The level of membrane staining of the receptors in EEC is not dependent on grading and staging, and is not sufficient to predict survival in EEC patients.</p> </abstract>